EUVIMEDEUVIMED entdecken
VergleichsstudieMetaanalyseSystematische Übersicht

Head-to-Head Comparison of the Diagnostic Performance of FDG PET/CT and FDG PET/MRI in Patients With Cancer: A Systematic Review and Meta-Analysis

Amit Singnurkar, Raymond Poon, Ur Metser

American Journal of Roentgenology · 2024-09 · 223 (3)

DOI: 10.2214/ajr.24.31519 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift American Journal of Roentgenology, 2024-09. Verfasst von Amit Singnurkar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Imaging, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Magnetic Resonance Imaging, Neoplasms, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND. The available evidence on the use of FDG PET/MRI performed using an integrated system in patients with cancer has grown substantially. OBJECTIVE. The purpose of this study was to perform a systematic review and meta-analysis comparing the diagnostic performance of FDG PET/CT and FDG PET/MRI in patients with cancer. EVIDENCE ACQUISITION. MEDLINE, Embase, and the Cochrane Database of Systematic Reviews were searched for studies reporting a head-to-head comparison of the diagnostic performance of FDG PET/CT and FDG PET/MRI in patients with cancer from July 1, 2015, to January 25, 2023. The two modalities' diagnostic performance was summarized, stratified by performance end point. For end points with sufficient data, a meta-analysis was performed using bivariate modeling to produce summary estimates of pooled sensitivity and specificity. For the remaining end points, reported performance in individual studies was recorded. EVIDENCE SYNTHESIS. The systematic review included 29 studies with a total of 1656 patients. For patient-level detection of regional nodal metastases (five studies), pooled sensitivity and specificity for PET/MRI were 88% (95% CI, 74-95%) and 92% (95% CI, 71-98%), respectively, and for PET/CT were 86% (95% CI, 70-94%) and 86% (95% CI, 68-95%). For lesion-level detection of recurrence and/or metastases (five studies), pooled sensitivity and specificity for PET/MRI were 94% (95% CI, 78-99%) and 83% (95% CI, 76-88%), respectively, and for PET/CT were 91% (95% CI, 77-96%) and 81% (95% CI, 72-88%). In individual studies not included in the meta-analysis, PET/MRI in comparison with PET/CT showed staging accuracy in breast cancer of 98.0% versus 74.5% and in colorectal cancer of 96.2% versus 69.2%; sensitivity for primary tumor detection in cervical cancer of 93.2% versus 66.2%; and sensitivity, specificity, and accuracy for lesion-level liver metastasis detection of 91.1-98.0% versus 42.3-71.1%, 100.0% versus 83.3-98.6%, and 96.5-98.2% versus 44.7-86.7%, respectively. In three studies, management was more commonly impacted by information from PET/MRI (5.2-11.1%) than PET/CT (0.0-2.6%). CONCLUSION. PET/MRI showed comparable or superior diagnostic performance versus PET/CT across a range of cancers and end points. CLINICAL IMPACT. The findings help to identify clinical settings where PET/MRI may provide clinical benefit for oncologic evaluation. TRIAL REGISTRATION. Prospective Register of Systematic Reviews CRD42023433857.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Magnetic Resonance ImagingNeoplasmsPositron Emission Tomography Computed TomographyRadiopharmaceuticalsHumansMultimodal ImagingPositron-Emission TomographySensitivity and Specificity

Stichwörter der Autor:innen

FDGPET/CTPET/MRImultimodal imagingoncology

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Medical Imaging, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Department of Oncology, Program in Evidence-Based Care, Ontario Health, Cancer Care Ontario, McMaster University, Juravinski Hospital and Cancer Centre, 711 Concession St, G Wing, 2nd Fl, Hamilton, ON L8V 1C3, Canada.
  • Department of Medical Imaging, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada.

Zitieren

APA

Singnurkar, A., Poon, R., & Metser, U. (2024). Head-to-Head Comparison of the Diagnostic Performance of FDG PET/CT and FDG PET/MRI in Patients With Cancer: A Systematic Review and Meta-Analysis. American Journal of Roentgenology, 223(3). https://doi.org/10.2214/ajr.24.31519

Vancouver

Singnurkar A, Poon R, Metser U. Head-to-Head Comparison of the Diagnostic Performance of FDG PET/CT and FDG PET/MRI in Patients With Cancer: A Systematic Review and Meta-Analysis. American Journal of Roentgenology. 2024;223(3). doi:10.2214/ajr.24.31519

BibTeX
@article{Singnurkar2024,
  author = {Singnurkar, Amit and Poon, Raymond and Metser, Ur},
  title = {Head-to-Head Comparison of the Diagnostic Performance of FDG PET/CT and FDG PET/MRI in Patients With Cancer: A Systematic Review and Meta-Analysis},
  journal = {American Journal of Roentgenology},
  year = {2024},
  volume = {223},
  number = {3},
  doi = {10.2214/ajr.24.31519}
}
Kostenlos starten →